Hormonal
Multi-receptor incretin drugs (Tirzepatide, Retatrutide, Mazdutide, Survodutide) produce substantial weight loss (>8kg) and glycemic control (HbA1c reduction >1%) in adults with overweight/obesity, with non-diabetic populations showing more pronounced effects than those with type 2 diabetes.
If you have overweight or obesity, multi-receptor incretin drugs like Tirzepatide or Retatrutide are highly effective for significant weight loss (often >10kg) and improving blood sugar control. These benefits are even more pronounced if you do not have type 2 diabetes. While gastrointestinal side effects are common, serious safety risks are not significantly higher than placebo. Consult a healthcare provider to determine if these medications are appropriate for your specific health profile.
Non-diabetic participants showed more pronounced improvements in both weight and blood pressure. ... Tirzepatide (MD: -12.78 kg... Retatrutide (MD: -11.91 kg... Mazdutide (MD: -5.31 kg... In patients with type 2 diabetes, all agents reduced HbA1c by over 1%... Non-diabetic individuals typically exhibit less insulin resistance or hyperglycemia, allowing them to derive more direct benefits from the blood pressure improvements associated with weight loss through multi-receptor drugs
Why this rating
Network meta-analysis of 24 RCTs with 9165 participants provides high-level evidence, though some individual drug comparisons have limited head-to-head data.
Source
Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis
Song Liu et al. · Frontiers in Endocrinology · 2025
DOI 10.3389/fendo.2025.1513641
More from this paper
- Multi-receptor incretin drugs significantly reduce systolic and diastolic blood pressure, with Tirzepatide and Mazdutide showing the most substantial reductions, particularly in non-diabetic populations.Good
- Multi-receptor incretin drugs are associated with an increased risk of adverse events (primarily gastrointestinal) compared to placebo, but do not significantly increase the risk of serious adverse events.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →